Global Epistaxis Device Market - 2022-2029
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global epistaxis device market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).
Epistaxis, or nose bleeding, is a common occurrence. It is rarely life-threatening. This clinical condition is classified as posterior epistaxis or anterior epistaxis, depending on where the bleeding starts.
The factors influencing the global epistaxis device market are the increasing demand for the treatment of epistaxis and the growing prevalence of epistaxis.
Epistaxis can come from either an anterior or posterior source, but it usually starts in the anterior nasal cavity. A detailed history and physical examination usually determine the cause of the bleeding. Both local and systemic processes can cause epistaxis. Nasal bleeding is usually treated with compression and other first-aid measures. When simple measures fail to relieve epistaxis, the source of the bleeding should be identified and treated appropriately. Topical vasoconstriction, chemical cautery, electrocautery, nasal packing (nasal tampon or gauze impregnated with petroleum jelly), posterior gauze packing, balloon therapy (including a modified Foley catheter), and arterial ligation or embolization are all options to consider. Antibiotics, either topical or systemic, should be used in certain patients. Moreover, RAPHID RHINO technology, a proprietary blend of CarboxyMethyl Cellulose, is used in Epistaxis products (CMC). This CMC-infused fabric has self-lubricating properties that turn into a gel consistency when wet, making it easier to insert and remove. The epistaxis solutions' ultra-low profile conforms quickly to anatomy and provides gentle, even compression to the nasal area.
Patients with anterior nosebleeds can be discharged after the bleeding has been controlled and hemodynamic stability observed for at least one hour in the emergency department (ED). All predisposing factors have been medically optimized. In one week, they should see an otolaryngologist or their primary care physician, and they should start using nasal saline three times per day. If non-biodegradable packing is used, patients should return to the ED or ENT in three to five days for packing removal. If a patient requires posterior packing, including pediatric patients, admission is required to monitor for complications, particularly cardiac arrhythmias. If discontinuation is not possible, all anticoagulants should be reversed or withheld to achieve the lowest dose acceptable. If appropriate equipment and follow-up are available, an anterior bleed can often be safely managed in primary care. If direct pressure fails to stop the bleeding, cautery or nasal packing are options. Silver nitrate is impregnated in cautery sticks, causing a chemical burn when it reacts with the mucosal lining. To avoid septal perforation, care must be taken during bilateral cautery, and treatment should be limited to a small area surrounding the bleeding point. After cauterization, patients should be put on a nasal moisturizer like Kenacomb or paraffin.
Due to the highly virulent nature of COVID-19 in respiratory droplets and nasal secretions, otolaryngologists are concerned about epistaxis management in COVID-19-positive patients. Another point of concern is the lack of mention of diagnostic nasal endoscopy. Nasal endoscopy aids in diagnosing a variety of mass lesions and provides a clear view of the nasal cavity and nasopharynx. It's also a procedure that's considered minimally invasive. As a result, it is recommended in cases where bleeding has stopped despite non-invasive measures. Another thing to think about is the role of posterior nasal packing in recommended cases and how important it is in the COVID-19 era. Hence, covid-19 has negatively affected the global epistaxis device market.
EPISTAXIS is a common clinical condition that has a variety of treatment options. The most common and traditional treatment for the posterior type of epistaxis is placing an inflated Foley catheter balloon in the nasopharynx and an anterior gauze pack. A typical description includes a 10 to 15 mL balloon inflation volume and the application of traction, which is maintained by sliding the catheter over a piece of plastic tubing and clamping the two tubes together.
The inflated Foley catheter balloon, for instance, may act as a stable platform in the nasopharynx for the insertion of an anterior gauze packing, which is solely responsible for stopping the epistaxis. In another mode of action, the balloon may compress the bleeding vessels and prevent bleeding down the oropharynx when effective traction is applied to the catheter. Although these and other theories offer plausible explanations for the Foley balloon's action in treating posterior epistaxis, none have been thoroughly investigated or described.
The growing prevalence of epistaxis and increasing research and development in this region is expected to drive the market growth.
A blood vessel inside the nose bursts, causing nosebleeds. Epistaxis is the medical term for nosebleeds. In the United States, up to 60 million people suffer from nosebleeds. They are most common in the winter when the cold weather and indoor heating exacerbate the dryness of the nasal passages.
The global epistaxis device market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Smith & Nephew, Stryker Corp., Teleflex Incorporated, SPIGGLE & THEIS Medizintechnik GmbH, Summit Medical LLC., EON Meditech
The global epistaxis device market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.
LIST NOT EXHAUSTIVE